Russian Federation announces completion of Covid-19 vaccine clinical trials

Russian Federation announces completion of Covid-19 vaccine clinical trials

"This gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans", Dr. Paul Stoffels, J&J's chief scientific officer, told Reuters in a telephone interview.

Health officials said the vaccine data would become available for review and publication early next month.

Meanwhile, Sanofi and GlaxoSmithKline said the United States government will pay $2.1 billion to them for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing. The vaccine found to be successful in tests on primates. Russian Federation is behind other developing vaccines that are in the third phase of their trials, as they will complete their second phase on August 3, and the third phase will be running when the medical workers are vaccinated.

According to the revised proposal, 1,600 people aged above 18 will participate in the trials across 17 selected sites including AIIMS Delhi, BJ Medical College, Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education & Research in Mysuru. Around the same time, the company will start a parallel phase 3 study testing a two-shot regimen of the vaccine, Stoffels said.

NASA launches new rover to search for signs of past Martian life
NASA's Mars 2020 perseverance rover had officially lifted for Mars from Florida in the United States on 30 th of July. The Mars Perseverance rover only has a short window of opportunity, and that was nearly missed due to the pandemic.

Last month, Russian scientists said that early-stage trials of an adenovirus-based vaccine developed by the Gamaleya Institute had been completed and that the results were a success. Six weeks after the immunization, all animals were exposed to SARS-CoV-2.

The research team developed a series of vaccine candidates created to express different variants of the SARS-CoV-2 spike protein, which is the major target for neutralizing antibodies.

Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the United Kingdom showed it has an acceptable safety profile and homologous boosting increased antibody responses, the source said.

J&J shares were up almost 2% at $149.72 before the bell on Thursday.

Related Articles